Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WJB001 + bevacizumab
- Development stage
- Unknown
- Lead developer
- Wigen Biomedicine Technology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral (for WJB001), Intravenous (for Bevacizumab)
01
Overview
WJB001 + bevacizumab is an investigational combination therapy currently being tested in advanced solid tumors. **WJB001** is an orally administered small molecule inhibitor targeting the Wee1-like protein kinase, a key regulator of the G2/M cell cycle checkpoint, being developed for tumors with **CCNE1 overexpression or amplification**, such as uterine serous carcinoma and high-grade serous ovarian, fallopian tube, or peritoneal cancers. **Bevacizumab** is a recombinant, humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), thereby blocking angiogenesis required for tumor growth. In this combination, WJB001 may potentiate anti-tumor activity through disruption of cell cycle checkpoints, while bevacizumab inhibits tumor vascularization, providing a multi-modal approach against advanced malignancies[1][2][4][7][9].
- Brand names
- Avastin (for bevacizumab)
- Other names
- WJB001 + Avastin
02
Targets
Beyond the preview
Go deeper on WJB001 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WJB001 + bevacizumab.